The information contained on this page is intended
for US healthcare professionals only.  Patient siteFREE SAMPLES/COUPONS

The information contained on this page is intended
for US healthcare professionals only.  Patient siteFREE SAMPLES/COUPONS

DISCOVER THE FIRST
AND ONLY LIQUID-FILLED
ASPIRIN CAPSULES®

With VAZALORE® your patients will receive all the benefits of immediate-release aspirin PLUS added protection

  • Bioequivalent to immediate-release/plain aspirin
  • Specially designed to help protect the stomach
Circular graphic including a silhouette image of a stomach with multiple circles inside to represent the fast, reliable absorption of Vazalore aspirin

Fast, reliable absorption

Circular graphic representing a bloodstream to symbolize the fast, predictable antiplatelet activity of Vazalore aspirin

Fast, predictable antiplatelet activity

Circular graphic representing the protection of the gastroduodenal mucosa from local GI injury that Vazalore aspirin can provide

Helps protect the gastroduodenal mucosa from local GI injury

A UNIQUE
delivery system for
this life-saving drug

VAZALORE IS AVAILABLE

over the counter.
Available in 81 mg and 325 mg
in stores nationwide.

Featuring a novel pharmaceutical lipid-aspirin complex formulation, VAZALORE is specifically designed to limit direct contact between aspirin and the stomach lining, providing the benefits of aspirin while optimizing bioavailability, absorption potential, and antiplatelet activity.¹

Product boxes shown side-by-side

Recommend the first and only liquid-filled ASPIRIN capsules®

Heart Protection with the Stomach in MINDTM

VAZALORE has a unique delivery system that is intended to release aspirin in the duodenum and decrease exposure to the stomach, which is the most susceptible part of the GI tract to NSAID-induced local gastric injury.

Opportunity for innovation in aspirin delivery

Reference:

  1. Angiolillo DJ, Bhatt DL, Lanza F, et al. Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study. J Thromb Thrombolysis. 2019;48(4):554-562.

Learn how
VAZALORE works
 

Read VAZALORE 325 mg
clinical results

Access VAZALORE
resources